|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Point mutations in different regions of the tumour necrosis factor-alpha (TNF-alpha) molecule influence anti-tumour cytotoxic/cytostatic activities as well as haemorrhagic tumour necrosis, tumour regression and lethal toxicity in mice.
|
1526652 |
1992 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Pretreatment with TNF for 72 h inhibited both TNF, tumor necrosis factor receptor (TNFR) p55, TNFR p75, and LPS-mediated activation of nuclear factor -kappa B (NF kappa B), whereas pretreatment with LPS only inhibited the LPS response.
|
7592709 |
1995 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These data suggest that whereas the p75 TNFR can both directly propagate TNF signals and "pass" TNF to the p55 TNFR, it attenuates LTalpha and may serve as a decoy receptor for this cytokine.
|
8621658 |
1996 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Histopathologic examination of the tumor mass from immunocompetent mice demonstrated centralized hemorrhagic tumor necrosis (38%) after inoculation of the HSV-TK-modified tumor cells and GCV in tumor-bearing mice compared with the control mice (5%), indicating that cytokines such as tumor necrosis factor-alpha (TNF-alpha) were being released locally.
|
8647234 |
1996 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
LPS, interleukin-1 (IL-1), and to a lesser extent tumor necrosis factor (TNF) significantly decreased MTP mRNA levels in hamster liver.These effects required several hours.
|
9643353 |
1998 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In particular, pro-apoptotic tumor necrosis factor (TNF) signals are blocked by proteins that are induced by NF-kappaB such as TNFR-associated factor 1 (TRAF1).
|
10692572 |
2000 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Moreover, reciprocal bone marrow transplantation experiments using TNF receptor-deficient mice revealed that TNF signals are equally pathogenic when directed independently to either bone marrow-derived or tissue stroma cell targets.
|
12486099 |
2002 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
DNA chip analysis revealed upregulation of TNF-alpha mRNA and a number of molecules involved in TNF-signaling such as TRAF-6, caspases-10, and -7 in depsipeptide-treated HL-60 cells, which prompted us to examine the involvement of the TNF/TNF receptor system in the anti-leukemic effects of the drug.
|
15515013 |
2005 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Tumour necrosis factor (TNF) signalling molecules are considered as promising therapeutic targets of antirheumatic therapy.
|
15642137 |
2005 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Of the genes deregulated in SMZLs, special mention may be made of the genes involved in B-cell receptor (BCR) signaling, tumor necrosis factor (TNF) signaling and nuclear factor-kappaB (NF-kappaB) activation, such as SYK, BTK, BIRC3, TRAF3, and LTB.
|
15914563 |
2005 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The extent of central tumor necrosis was decreased in the tumors in NFATc2((-/-)) mice, and this finding was associated with reduced tumor necrosis factor-alpha and interleukin-2 (IL-2) production by CD8(+) T cells.
|
19318584 |
2009 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Tumour necrosis factor (TNF) significantly increased fractalkine mRNA (>100 fold) and protein expression, which was associated with increased shedding of fractalkine from the cell.
|
19324423 |
2009 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CD40, CD80, CD86 and major histocompatibility complex (MHC) class II], as well as the production of cytokines [e.g. interleukin (IL)-1β, IL-12p70 and tumour necrosis gactor (TNF)-α] compared with those of unstimulated controls.
|
21910723 |
2011 |
|
Tumor necrosis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Several rheumatoid arthritis (RA) susceptibility variants map close to genes involved in the tumor necrosis factor (TNF) signaling pathway, prompting the investigation of RA susceptibility variants in studies of predictors of response to TNF blockade.
|
21952740 |
2012 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In this study, we investigated the effects of tumor necrosis factor (TNF) signaling on spatiotemporal enhancer-promoter interactions in the human tumor necrosis factor (TNF)/lymphotoxin (LT) gene locus, mediated by CCCTC-binding factor (CTCF)-dependent chromatin insulators.
|
22354988 |
2012 |
|
Tumor necrosis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
After lenalidomide treatment, genes involved in the tumor necrosis factor (TNF) signaling pathway that were upregulated in the patients before treatment decreased to the healthy control baseline expression level.
|
22608605 |
2012 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These effects can be explained by the diverse cellular responses TNF can initiate through distinct signal transduction pathways, opening the way for more selective targeting of TNF signalling in cancer therapy.
|
23460481 |
2013 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Therefore, the overall magnitude of tumor cell killing results from the combination of oncolysis, transgene-mediated direct effect such as TNFa-mediated apoptosis, and, perhaps most significantly, from activation of the host immune system against the tumor.
|
25557131 |
2015 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
To this end, we identified TNBC-driven molecular pathways such as the Janus kinase-signal transducers, and activators of transcription (JAK-STAT) and tumor necrosis factor (TNF) signaling pathways.
|
25611337 |
2015 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The tumor necrosis factor (TNF) signaling pathway is a classical immune system pathway that plays a key role in regulating cell survival and apoptosis.
|
25912078 |
2015 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Using anti-TNF treatment and TNF-receptor-deficient mice, here we show that Bin cells are induced and maintained independently of B cell-intrinsic TNF signals.
|
25959608 |
2015 |
|
Tumor necrosis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
These humoral factors can generally be divided into those which, like RANKL, are tumour necrosis family (TNF) superfamily members and those which are not; the former include TNFα lymphotoxin exhibiting inducible expression and competing with herpes simplex virus glycoprotein D for herpesvirus entry mediator, a receptor expressed by T lymphocytes (LIGHT), a proliferation inducing ligand (APRIL) and B cell activating factor (BAFF); the latter include transforming growth factor beta (TGF-β), interleukin-6 (IL-6), IL-8, IL-11, nerve growth factor (NGF), insulin-like growth factor-I (IGF-I) and IGF-II.
|
26578261 |
2016 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
TNF-α inhibition resulted in suppression of IL-6 and IL-8 in parallel with clinical improvement in all anti-TNF-treated subjects, but was also associated with elevated TNF-α and IL-17 in etanercept-treated subjects.
|
26934060 |
2016 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Computational analyses revealed that 28 of the differentially expressed (DE) mRNAs were associated with eight DE lncRNAs involved in chemokine signaling pathways, the nuclear factor-kappa B (NF-κB) signaling pathway, and tumor necrosis factor (TNF) signaling pathway.
|
27188286 |
2016 |
|
Tumor necrosis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Tumor necrosis factor-α (TNF-α)-induced protein 8-like-2 (TNFAIP8L2 or TIPE2), a member of the tumor necrosis TNFAIP8 family, was found to be involved in the development and progression of several tumors.
|
28081733 |
2017 |